54741_Image_jpeg.jpg
Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care
04 août 2021 08h30 HE | Daxor Corporation
Data Led to Multi-Center Study In Progress At Three Leading Hospitals Oak Ridge, TN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100® (Blood Volume Analyzer) with the United States Department of Veterans Affairs
06 mai 2021 08h30 HE | Daxor Corporation
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical...
54741_Image_jpeg.jpg
Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)
29 avr. 2021 08h31 HE | Daxor Corporation
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility...
54741_Image_jpeg.jpg
Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020
26 févr. 2021 08h30 HE | Daxor Corporation
Revenues of Operating Division Increase by 50.4% NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) The global leader in blood volume technology today filed its Annual...
54741_Image_jpeg.jpg
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering
20 juil. 2020 09h09 HE | Daxor Corporation
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology...